3Timmermans PBMWM,Wag PC.The preclinical basis of the therapeutic evaluation of lorsartan[J]JHypertens,1995,13(1):1.
4Garg Jay,Bakris,George L.Angiotensin converting enzyme inhibitors or angio-tensin receptor blockers in nephropathy from type 2 diabetes[J].CurrHypertens Rep,2002,4(3):185.
1[1]Wolf G, Znyadeh FN. The role of angiotensin Ⅱ in diabetic nephropathy emphasis on nonhemodynamic mechanisms. Am J Kid Dis, 1997; 29(1):153
2[2]Timmermans PBMWM, Wag PC. The preclinical basis of the therapeutic evluation of lorsartan. J Hypertens, 1995; 13 (1):S1
3[4]Garg Jay, Bakris, George L. Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes. Curr Hypertens Rep, 2002; 4(3):185
4[5]Gilbert RE, CoxG, WuLL, et al. Expression of transforming growth factor β and type Ⅳ collagen in the renal tubulointerstitium in experimental diabetes effects of ACE inhibition. Diabetes, 1998; 47(1):414
5[6]Andersen S, Tarnow L, Rossing P, et al. Renoprotective effects of angiotensin Ⅱ receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int, 2000; 57(2):601
6A. Flyvbjerg,K. E. Bornfeldt,S. M. Marshall,H. J. Arnqvist,H. ?rskov. Kidney IGF-I mRNA in initial renal hypertrophy in experimental diabetes in rats[J] 1990,Diabetologia(6):334～338
7A. R. Andersen,J. Sandahl Christiansen,J. K. Andersen,S. Kreiner,T. Deckert. Diabetic nephropathy in type 1 (insulin-dependent) diabetes: An epidemiological study[J] 1983,Diabetologia(6):496～501
